An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.

[1]  S. Arron,et al.  Histologic changes in basal cell carcinoma after treatment with vismodegib. , 2013, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[2]  V. Elner,et al.  Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma. , 2013, JAMA ophthalmology.

[3]  A. Chang,et al.  Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. , 2013, JAMA dermatology.

[4]  A. Wysong,et al.  Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. , 2013, JAMA dermatology.

[5]  T. Akcam,et al.  Nonmelanoma skin cancer of the head and neck: surgical treatment. , 2012, Facial plastic surgery clinics of North America.

[6]  A. Cognetta,et al.  Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. , 2012, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[7]  S. van der Geer,et al.  Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study , 2012, The British journal of dermatology.

[8]  Kris Chang,et al.  Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. , 2012, The New England journal of medicine.

[9]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[10]  J. Paoli,et al.  5-year recurrence rates of Mohs micrographic surgery for aggressive and recurrent facial basal cell carcinoma. , 2011, Acta dermato-venereologica.

[11]  B. Gastman,et al.  What Is the Best Surgical Margin for a Basal Cell Carcinoma: A Meta-Analysis of the Literature , 2010, Plastic and reconstructive surgery.

[12]  D. Ratner,et al.  Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. , 2009, Archives of dermatology.

[13]  E. Epstein.  Basal cell carcinomas: attack of the hedgehog , 2008, Nature Reviews Cancer.

[14]  P. Friedman,et al.  Curettage prior to Mohs' Micrographic Surgery for Previously Biopsied Nonmelanoma Skin Cancers: What Are We Curetting? Retrospective, Prospective, and Comparative Study , 2005, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[15]  P. Nelemans,et al.  Mohs' micrographic surgery for treatment of basal cell carcinoma of the face——results of a retrospective study and review of the literature , 2004, The British journal of dermatology.

[16]  J. Thornby,et al.  Correlation of histologic subtypes of primary basal cell carcinoma and number of Mohs stages required to achieve a tumor-free plane. , 1997, Journal of the American Academy of Dermatology.

[17]  M A Weinstock,et al.  Nonmelanoma skin cancer in the United States: incidence. , 1994, Journal of the American Academy of Dermatology.

[18]  R. Carroll,et al.  Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. , 1989, The Journal of dermatologic surgery and oncology.

[19]  R. Siegle,et al.  Infiltrative basal cell carcinoma: a nonsclerosing subtype. , 1986, The Journal of dermatologic surgery and oncology.